Evaluation of labelingparameters of PSMA-617 with 213Bi for targeted alpha-radionuclide therapy of metastatic castration-resistant prostate cancer

被引：0
|
作者：
Khoshhosn, H. [1 ]
Davarpanah, M. [1 ]
Khoshhosn, H. [1 ]
Gravand, A. [1 ]
Tavakoli, Y. [1 ]
Soltani, N. [1 ]
Harati, M. [1 ]
Kalantari, B. [1 ]
Johri, F. [1 ]
机构：
[1] Pars Isotope Co, Tehran, Iran
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-720
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [1] 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
    Sathekge, Mike
    Knoesen, Otto
    Meckel, Marian
    Modiselle, Moshe
    Vorster, Mariza
    Marx, Sebastian
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) : 1099 - 1100
  • [2] 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
    Mike Sathekge
    Otto Knoesen
    Marian Meckel
    Moshe Modiselle
    Mariza Vorster
    Sebastian Marx
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1099 - 1100
  • [3] PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
    Kratochwil, Clemens
    Giesel, Frederik L.
    Stefanova, Melsa
    Benesova, Martina
    Bronzel, Marcus
    Afshar-Oromieh, Ali
    Mier, Walter
    Eder, Matthias
    Kopka, Klaus
    Haberkorn, Uwe
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (08) : 1170 - 1176
  • [4] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Derlin, Thorsten
    Schmuck, Sebastian
    LANCET ONCOLOGY, 2018, 19 (08): : E372 - E372
  • [5] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Sandhu, Shahneen
    LANCET ONCOLOGY, 2018, 19 (08): : E373 - E373
  • [6] Labeling of DKFZ-PSMA-617 with 213Bi in routine clinical practice for alpha-emitter based therapy of metastatic castration-resistant prostate cancer
    Mueller, Dirk
    Klette, Ingo
    Kulkarni, Harshad
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [7] Simple method for production and quality control of 225Ac- PSMA-617 for the targeted alpha therapy of castration-resistant prostate cancer.
    Khoshhosn, H.
    Dayeni, M.
    Pirdadeh, M.
    Ghapanvari, M.
    Tavakoli, Y.
    Samizadeh, M.
    Mazidi, M.
    Nami, R.
    Soltani, N.
    Movahhed, H.
    Gravand, A.
    Sarabi, A.
    Davarpanah, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S674 - S675
  • [8] Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Tripathi, Madhavi
    Seth, Amlesh
    Bal, Chandrasekhar
    THERANOSTICS, 2020, 10 (20): : 9364 - 9377
  • [9] Efficacy and Safety of 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, M.
    Ballal, S.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S420 - S420
  • [10] Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02) : 106 - 106
12345